news
-
20 October 2020Genkyotex’s setanaxib granted Orphan Drug Designation by the US FDA for the treatment of PBC
Genkyotex (Euronext Paris & Brussels: FR0013399474 – GKTX), a biopharmaceutical company and leader in NOX therapies, today announced that its lead drug candidate, setanaxib, has been granted orphan drug designation (ODD) by the US Food and Drug Administration (FDA) for the treatment of primary biliary cholangitis (PBC).
Elias Papatheodorou, CEO of Genkyotex, comments: “Obtaining the ODD from the FDA is of strategic importance for the development of setanaxib in PBC. The FDA and the European Medicines Agency (EMA) have also granted ODD for setanaxib in the treatment of idiopathic pulmonary fibrosis and systemic sclerosis, highlighting the compound’s therapeutic potential in multiple fibrotic disorders with high unmet needs.”
Orphan Drug Designation is granted by the FDA to drugs or biological products intended for the safe and effective treatment of rare diseases with an unmet medical need, affecting fewer than 200,000 people in the United States. Among other benefits beyond the clinical development phases of the product, ODD provides 7 years of market exclusivity after obtaining marketing approval in the United States. In addition, in certain cases, it may provide tax credits on clinical research expenses, an accelerated registration procedure, technical assistance to complete the registration file as well as exemptions from filing fees with the regulatory agencies.
The company is currently discussing its registration strategy for setanaxib in PBC with the FDA and the EMA. Genkyotex will provide an outline of its late stage development plan once final approval of a common registration strategy has been obtained from these regulatory agencies.
Related
Genkyotex announces first-half 2020 results and business update
Genkyotex Provides Business Update and Reports Cash Position at June 30, 2020
Genkyotex announces the dosing of the first subjects in its Phase 1 study with high-dose setanaxib
Genkyotex Provides Business Update and Reports Cash Position at March 31, 2020
Genkyotex Provides Business Update and Reports Gross Cash Position at December 31, 2019
Genkyotex reports progress of Setanaxib phase 2 investigator initiated trials
Genkyotex provides business update and reports cash position at September 30, 2019
Genkyotex Announces First Half 2019 Results
The Who recognizes Nox Inhibitors as New Therapeutic Class and Approves Setanaxib for GKT831
Genkyotex Announces FDA Approval of Phase 2 InvestigatorInitiated Trial with GKT831 in IPF
Genkyotex’s GKT831 Prevents Multiple Complications of Portal Hypertension in Preclinical Model
Genkyotex Reports Clinical Evidence of Anti-fibrotic Activity by GKT831 in Liver Fibrosis Patients
Genkyotex provides Corporate Update and Reports Cash position at March 31, 2019
Genkyotex Reverse Stock Split Takes Effect
Genkyotex announces 2018 Annual Financial Results and provides Corporate update
Launch of the reverse stock split of Genkyotex shares
Genkyotex provides corporate update and reports cash position at December 31, 2018
Preclinical Efficacy of Genkyotex’s GKT831 in Prostate Cancer Presented at ESUR18 Meeting
Genkyotex provides update on PBC Phase 2 Trial and Reports June 30, 2018, Cash Position
Genkyotex expands License Agreement for Vaxiclase Platform with Serum Institute of India
Genkyotex Announces Leadership Transition
Genkyotex’s NOX1&4 Inhibitor Strategy in Liver Fibrosis Supported by New Preclinical Results